GlassScriptPhysician profile
Amita Heaser
NPI 1902062219
$2,288.33
in general payments reported to CMS, 2019-2025
29 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $258 · 2021: $394 · 2022: $517 · 2023: $323 · 2024: $332 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.96 | 2020-2025 | |
| Glaxosmithkline, LLC. | $213.02 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $200.05 | 2020-2023 | Freestyle Libre |
| Novo Nordisk INC | $196.49 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Insmed, INC. | $179.50 | 2023-2024 | Arikayce |
| Amgen INC. | $147.84 | 2019-2024 | Repatha, Otezla, Prolia |
| Dexcom, INC. | $116.71 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $101.47 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $78.61 | 2020-2022 | |
| Lilly USA, LLC | $69.44 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $67.85 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.55 | 2019-2024 | Ofev |
| Viiv Healthcare Company | $48.71 | 2024 | Dovato |
| Amarin Pharma, INC. | $45.97 | 2020-2021 | |
| Allergan, INC. | $42.20 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38.56 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $35.59 | 2019 | |
| Sumitomo Pharma America, INC. | $30.55 | 2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $27.12 | 2021 | |
| Astellas Pharma US INC | $25.30 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.14 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.79 | 2025 | Caplyta |
| Horizon Therapeutics Plc | $17.96 | 2022 | |
| Exact Sciences Corporation | $16.33 | 2025 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $14.91 | 2019 | |
| Merck Sharp & Dohme LLC | $13.86 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.68 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amita Heaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.